A double-blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia.
A double-blind comparison of fluspirilene and fluphenazine decanoate in 28 schizophrenic patients over six months showed equal improvement and the same incidence of side-effects in each group of patients. It would be expected from the literature that a better ratio of therapeutic to side-effects would appear with fluspirilene than with fluphenazine. The absence of such an effect in this study may be attributable to an initial lack of familiarity by the investigators with the use of fluspirilene, indicating an important potential variable in the comparison of a new drug with an established one.
D000328:Adult; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D005260:Female; D005476:Fluphenazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005484:Fluspirilene / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy*; D012563:Schizophrenia, Paranoid / Q000188:drug therapy; D012565:Schizophrenic Psychology; D013141:Spiro Compounds / Q000627:therapeutic use*
D013141:Spiro Compounds; D005484:Fluspirilene; C011825:fluphenazine depot; D005476:Fluphenazine